Why the AFT Pharmaceuticals (ASX:AFP) share price is in focus

The AFT Pharmaceuticals (ASX: AFP) share price is one to watch today after the company signed a new US licensing deal with a major supplier.

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AFT Pharmaceuticals Ltd (ASX: AFP) share price is one to watch this morning.

Shares in the Kiwi-Australian pharmaceuticals group could be on the move after the company announced a new licensing agreement in the United States.

Why is the AFT Pharmaceuticals share price in focus?

This morning, the company announced the signing of an exclusive license and distribution agreement with Hikma Pharmaceuticals USA ("Hikma"). The new deal is to commercialise Maxigesic IV in the United States with the major pharmaceuticals supplier.

Maxigesic IV is an intravenous, opioid free, postoperative pain relief medicine developed by AFT. Today's agreement represents the first out-license of the Maxigesic family of medicines in the US market.

That's an important milestone for the company and the AFT Pharmaceuticals share price is one to watch as a result. In today's release, AFT also said it was targeting the US market for the tablet and liquid forms of the medication in the longer term.

What are the terms?

Under the terms of the agreement, Hikma will have exclusive rights for the sales, marketing and distribution of Maxigesic IV in the US. AFT will receive upfront, regulatory and commercial milestone payments of up to US$18.8 million in return.

The milestone payments comprise US$7.5 million based on triggers leading up to and including registration and first commercial sale of the product. US$3.6 million of those will be earned once Food and Drug Administration (FDA) approval is received. The trans-Tasman pharma group will also receive a profit share from in market product sales.

That's potentially big news which puts the AFT Pharmaceuticals share price on watch this morning. Shares in the pharma group are down 28.0% in 2021 with a market capitalisation of $381.6 million prior to the open.

Foolish takeaway

Hikma is the third largest US supplier of generic injectable medicines by volume. AFT also said it is working to complete FDA approval for the tablet form of the medication.

Investors will be watching the AFT Pharmaceuticals share price ahead of its audited financial results in May.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »